Cambridge Healthtech Institute’s 9th Annual

Clinical Progress of Antibody-Drug Conjugates
( 抗体薬物複合体の臨床開発の進展 )

Advancing Novel ADC Platforms and Combinations to the Clinic



Antibody-drug conjugates (ADCs) continue to emerge as a strong and promising strategy for target cancer therapy. Today, there are four ADCs approved and commercially available in the US, with another 175 investigational ADCs in development, from early discovery to clinical phase III trials, across both hematologic malignancies and solid tumor indications. Some of these trials are single-agent trials, while others are combinations. Companies are leveraging on lessons learned from first and second-generation trials to inform on next-generation ADC designs.

In this second installment of our 2-part ADC program, PEGS Boston’s 9th Annual Clinical Progress of Antibody-Drug Conjugates will invite investigators to share their latest results from preclinical and clinical trials, lessons learned to optimize clinical trial design, address toxicity concerns, and develop better predictability for translation from bench to clinic.


Coverage will include, but is not limited to:


  • Tales from the clinic – novel ADC platforms in
    • Monotherapy Trials
    • Combination therapy Trials
  • Optimizing clinical trial design – biomarkers, patient stratification and dosing
  • Addressing toxicity issues in preclinical and clinical outcomes
    • Preclinical and translational updates
      • Effective mouse models
      • Examining preclinical translatability and predictability of clinical results
      • Using in silico modeling and predictive analytics in translational science
      • Regulatory complexities and considerations

      * 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

      Choose your language
      Traditional Chinese
      Simplified Chinese